3 February 2021 - GlaxoSmithKline's Nucala (mepolizumab) will be funded on the NHS in England and Wales for treating patients with severe eosinophilic asthma.

Specifically, Nucala, as an add-on therapy, is recommended as an option for treating severe refractory eosinophilic asthma in adults who have agreed to follow an optimised standard treatment plan, with a recorded blood eosinophil count of 300 cells/mcL or more.

Read Pharma Times article